Epigenetic therapy in myeloproliferative neoplasms: Evidence and perspectives

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 8 A, 2009, Pages 1437-1450

  Vannucchi, Alessandro M ^a,b,d   Guglielmelli, Paola ^a,b   Rambaldi, Alessandro ^c   Bogani, Costanza ^a,b   Barbui, Tiziano ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Epigenetics; Histone deacetylases; JAK2 mutation; Methylation; MPL mutation; Myeloproliferative neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; ARTICLE; GENETIC EPIGENESIS; GENETICS; HUMAN; LEUKEMIA; MYELOPROLIFERATIVE DISORDER; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; EPIGENESIS, GENETIC; HUMANS; LEUKEMIA; MYELOPROLIFERATIVE DISORDERS;

MYELOPROLIFERATIVE LEUKEMIA VIRUS;

EID: 70349308652     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00827.x     Document Type: Article

References (175)

1. Swertllow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon : International Agency for Research on Cancer 2008.
2. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951 6 : 372 375.
3. Spivak JL. Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry. Semin Hematol. 2003 40 : 1 5.
4. Tefferi A, Gangat N, Wolanskyj AP, et al. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. Eur J Haematol. 2008 80 : 386 390.
5. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007 110 : 1092 1097.
6. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes poly-cythaemia vera. Nature. 2005 434 : 1144 1148. (Pubitemid 40663494)
7. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005 365 : 1054 1061.
8. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 7 : 387 397.
9. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 352 : 1779 1790. (Pubitemid 40570926)
10. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006 3 : e270.
11. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007 356 : 459 468.
12. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006 355 : 2452 2466.
13. Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007 7 : 673 683.
14. Kaushansky K. The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age. Best Pract Res Clin Haematol. 2007 20 : 5 12.
15. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009 59 : 171 191.
16. Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia. 2008 22 : 1494 1502.
17. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007 109 : 68 76.
18. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007 31 : 737 740.
19. Harrison CN, Green AR. Essential thrombocythaemia. Best Pract Res Clin Haematol. 2006 19 : 439 453.
20. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005 23 : 2224 2232.
21. Tefferi A. Primary myelofibrosis. Cancer Treat Res. 2008 142 : 29 49.
22. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005 105 : 2664 2670.
23. Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev. 2005 19 : 243 252.
24. Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986 23 : 132 143.
25. Policitemia GIS. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med. 1995 123 : 656 664.
26. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004 350 : 114 124. (Pubitemid 38056222)
27. Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997 34 : 17 23.
28. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 332 : 1132 1136.
29. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 353 : 33 45.
30. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004 117 : 755 761.
31. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981 304 : 441 447.
32. Barosi G. Myelofibrosis with myeloid metaplasia. Hematol Oncol Clin North Am. 2003 17 : 1211 1226.
33. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008 22 : 905 914.
34. Cervantes F, Dupriez B, Pereira A, et al. A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2008 113 : 2895 2901.
35. Kroger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia. 2008 22 : 474 486.
36. Jones AV, Silver RT, Waghorn K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood. 2006 107 : 3339 3341.
37. Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008 22 : 1990 1998.
38. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated Interferon-alfa-2a induces complete hematological and molecular responses with low toxicity in polycythemia vera. Blood. 2008 112 : 3065 3072.
39. Kundrapu K, Colenberg L, Duhe RJ. Activation loop tyrosines allow the JAK2(V617F) mutant to attain hyperactivation. Cell Biochem Biophys. 2008 52 : 103 12.
40. Vainchenker W, Constantinescu SN. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology Am Soc Hematol Educ Program. 2005 195 200.
41. Wernig G, Mercher T, Okabe R, et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006 107 : 4274 4281.
42. Lacout C, Pisani DF, Tulliez M, et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006 108 : 1652 1660.
43. Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 2006 66 : 11156 11165.
44. Zaleskas VM, Krause DS, Lazarides K, et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE. 2006 1 : e18.
45. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008 111 : 3931 3940.
46. Shide K, Shimoda HK, Kumano T, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F Leukemia. 2007 22 : 87 95.
47. Verstovsek S, Silver RT, Cross NC, et al. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? Leukemia. 2006 20 : 2067.
48. Vizmanos JL, Ormazabal C, Larrayoz MJ, et al. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. Leukemia. 2006 20 : 534 535.
49. Szpurka H, Tiu R, Murugesan G, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood. 2006 108 : 2173 2181.
50. Renneville A, Quesnel B, Charpentier A, et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia. 2006 20 : 2067 2070.
51. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2007 111 : 1686 1689.
52. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006 108 : 3472 3476.
53. Guglielmelli P, Pancrazzi A, Bergamaschi G, et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol. 2007 137 : 244 247.
54. Beer PA, Campbell P, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008 112 : 141 149.
55. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood. 2008 112 : 844 847.
56. Chaligne R, Tonetti C, Besancenot R, et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G(1)/S-phase transition. Leukemia. 2008 22 : 1557 1566.
57. Lasho TL, Pardanani A, McClure RF, et al. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol. 2006 135 : 683 687.
58. James C. The JAK2V617F Mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases? Hematology Am Soc Hematol Educ Program. 2008 2008 : 69 75.
59. Vannucchi AM, Guglielmelli P. Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations. Haematologica. 2008 93 : 972 976.
60. Skoda R. The genetic basis of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program. 2007 2007 : 1 10.
61. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007 35 : 32 8.
62. Delhommeau F, Dupont S, James C, et al. TET2 is a novel tumor suppressor gene inactivated in myeloproliferative neoplasms: identification of a pre-JAK2 V617F event. Blood. 2008 112 : lba 3A.
63. Pardanani A, Fridley BL, Lasho TL, et al. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood. 2008 111 : 2785 2789.
64. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005 366 : 1945 1953.
65. Holliday R. The inheritance of epigenetic defects. Science. 1987 238 : 163 170.
66. Jenuwein T, Allis CD. Translating the histone code. Science. 2001 293 : 1074 1080.
67. Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008 40 : 741 750.
68. Esteller M. Epigenetics in cancer. N Engl J Med. 2008 358 : 1148 1159.
69. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev. 2007 8 : 286 298.
70. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007 16 : 50 9.
71. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev. 2004 18 : 2315 2335.
72. Weber M, Davies JJ, Wittig D, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet. 2005 37 : 853 862.
73. Eden A, Gaudet F, Waghmare A, et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003 300 : 455.
74. Gaudet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. Science. 2003 300 : 489 492.
75. Xu GL, Bestor TH, Bourc'his D, et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature. 1999 402 : 187 191.
76. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003 349 : 2042 2054.
77. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res. 2001 61 : 3225 3229.
78. Bachman KE, Herman JG, Corn PG, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 1999 59 : 798 802.
79. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev. 2002 3 : 415 428.
80. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999 21 : 103 107.
81. Bartel D P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004 116 : 281 297.
82. Ambros V, Chen X. The regulation of genes and genomes by small RNAs. Development. 2007 134 : 1635 1641.
83. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005 433 : 769 773.
84. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006 6 : 857 866.
85. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005 120 : 635 647.
86. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005 102 : 13944 13949.
87. Garzon R, Croce CM. MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol. 2008 15 : 352 358.
88. Zhao H, Kalota A, Jin S, et al. The c-myb protooncogene and microRNA (miR)-15a comprise an active autoregulatory feedback loop in human hematopoietic cells. Blood. 2008 113 : 505 516.
89. Fazi F, Rosa A, Fatica A, et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granu-lopoiesis. Cell. 2005 123 : 819 831.
90. Weber B, Stresemann C, Brueckner B, et al. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle. 2007 6 : 1001 1005.
91. Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007 67 : 1424 1429.
92. Varambally S, Cao Q, Mani RS, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltrans-ferase EZH2 in cancer. Science. 2008 322 : 1695 1699.
93. Opalinska J, Sohal D, Parmar S, et al. A high resolution epigenomic map of myelofibrosis reveals multiple chromosomal deletions and amplifications accompanied by a high level of functionally important methylation. Blood. 2006 110 : 2120A.
94. Wang JC, Chen C, Dumlao T, et al. Enhanced histone deacethylase enzyme activity in primary myelofibrosis. Leuk Lymph. 2008 49 : 2321 2327.
95. Valentino L, Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol. 2006 71 : 713 721.
96. Hookham MB, Elliott J, Suessmuth Y, et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood. 2007 109 : 4924 4929.
97. Kishimoto T, Kikutani H. Knocking the SOCS off a tumor suppressor. Nat Genet. 2001 28 : 4 5.
98. Liu TC, Lin SF, Chang JG, et al. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Brit J Haematol. 2003 123 : 645 661.
99. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. Haematologica. 2004 89 : 42 8.
100. Teofili L, Martini M, Cenci T, et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer. 2008 123 : 1586 1592.
101. Fourouclas N, Li J, Gilby DC, et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica. 2008 93 : 1635 1644.
102. Capello D, Deambrogi C, Rossi D, et al. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol. 2008 141 : 504 511.
103. Fernandez-Mercado M, Cebrian V, Euba B, et al. Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms. Leuk Res. 2008 32 : 1638 1640.
104. Chen CY, Tsay W, Tang JL, et al. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chrom Canc. 2003 37 : 300 305.
105. Watanabe D, Ezoe S, Fujimoto M, et al. Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol. 2004 126 : 726 735.
106. Hatirnaz O, Ure U, Ar C, et al. The SOCS-1 gene methylation in chronic myeloid leukemia patients. Am J Hematol. 2007 82 : 729 730.
107. Wu SJ, Yao M, Chou WC, et al. Clinical implications of SOCS1 methylation in myelodysplastic syndrome. Br J Haematol. 2006 135 : 317 323.
108. Jost E, do ON, Dahl E, et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia. 2007 21 : 505 510.
109. Temerinac S, Klippel S, Strunck E, et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily which is over-expressed in polycythemia rubra vera. Blood. 2000 95 : 2569 2576.
110. Jelinek J, Li J, Mnjoyan Z, et al. Epigenetic control of PRV-1 expression on neutrophils. Exp Hematol. 2007 35 : 1677 1683.
111. Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood. 2001 98 : 3249 3255.
112. Guglielmelli P, Zini R, Bogani C, et al. Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). Stem Cells. 2007 25 : 165 173.
113. Rosti V, Massa M, Vannucchi AM, et al. The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis. 2007 38 : 280 286.
114. Bogani C, Ponziani V, Guglielmelli P, et al. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells. 2008 26 : 1920 1930.
115. Shi J, Zhao Y, Ishii T, et al. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res. 2007 67 : 6417 6424.
116. Wang X, Zhang W, Ishii T, et al. Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin modifying agents. Blood. 2008 112 : 101A.
117. Shi S, Calhoun HC, Xia F, et al. JAK signaling globally counteracts heterochro-matic gene silencing. Nat Genet. 2006 38 : 1071 1076.
118. Zhang Q, Wang HY, Woetmann A, et al. STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood. 2006 108 : 1058 1064.
119. Guglielmelli P, Tozzi L, Pancrazzi A, et al. MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol. 2007 35 : 1708 1718.
120. Bruchova H, Merkerova M, Prchal JT. Aberrant expression of microRNA in polycythemia vera. Haematologica. 2008 93 : 1009 1016.
121. Bruchova H, Yoon D, Agarwal AM, et al. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol. 2007 35 : 1657 1667.
122. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006 24 : 166 173.
123. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993 7 : 21 9.
124. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006 24 : 3895 3903.
125. Maslak P, Chanel S, Camacho LH, et al. Pilot study of combination transcriptional modulation therapy with sodium phenyl-butyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia. 2006 20 : 212 217.
126. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007 110 : 2302 2308.
127. Kantarjian H, Issa J P, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006 106 : 1794 1803.
128. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 109 : 52 7.
129. Issa J P, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005 23 : 3948 3956. (Pubitemid 46218698)
130. Oki Y, Kantarjian HM, Gharibyan V, et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 2007 109 : 899 906.
131. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007 25 : 84 90.
132. Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA. 2005 102 : 3697 3702.
133. Khan O, La Thangue NB. Drug insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nature Clin Pract. 2008 5 : 714 726.
134. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008 111 : 1060 1066.
135. Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase I/II study of vorinostat, an oral histone deacethylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndromes and acute myeloid leukemia (AML). Initial results of the phase I trial: a New York Cancer Consortium. J Clin Oncol. 2008 26 : 7000A.
136. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. 2004 104 : 1266 1269.
137. Kuendgen A, Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer. 2007 110 : 943 954.
138. Raffoux E, Chaibi P, Dombret H, et al. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica. 2005 90 : 986 988.
139. Pilatrino C, Cilloni D, Messa E, et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer. 2005 104 : 101 109.
140. Bug G, Ritter M, Wassmann B, et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer. 2005 104 : 2717 2725.
141. Golay J, Cuppini L, Leoni F, et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia. 2007 21 : 1892 1900.
142. Leoni F, Zaliani A, Bertolini G, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA. 2002 99 : 2995 3000.
143. Carta S, Tassi S, Semino C, et al. Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. Blood. 2006 108 : 1618 1626.
144. Galli M, Salmoiraghi S, Golay J, et al. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma: preliminary results. Blood. 2007 110 : 1175A.
145. Miranda KC, Huynh T, Tay Y, et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell. 2006 126 : 1203 1217.
146. Zhang B, Wang Q, Pan X. MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol. 2007 210 : 279 289.
147. Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007 302 : 1 12.
148. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005 438 : 685 689.
149. Krutzfeldt J, Kuwajima S, Braich R, et al. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res. 2007 35 : 2885 2892.
150. Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007 13 : 613 618.
151. Felicetti F, Errico MC, Bottero L, et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res. 2008 68 : 2745 2754.
152. Fontana L, Fiori ME, Albini S, et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE. 2008 3 : e2236.
153. Mercatelli N, Coppola V, Bonci D, et al. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE. 2008 3 : e4029.
154. Quintas-Cardama A, Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/ polycythemia vera myelofibrosis. Leukemia. 2008 22 : 965 970.
155. Mesa RA, Verstovsek S, Rivera C, et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia. 2008 23 : 180 182.
156. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006 108 : 1497 1503.
157. Yang AS, Estecio MR, Doshi K, et al. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res. 2004 32 : e38.
158. Odenike OM, Godwin JE, Van Besien K, et al. Phase II trial of low dose, subcutaneous decitabine in myelofibrosis. Blood. 2008 112 : 2809A.
159. Guerini V, Barbui V, Spinelli O, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia. 2008 22 : 740 747.
160. Rambaldi A, Dellacasa CM, Salmoiraghi S, et al. A phase 2A study of the histone-deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms. Blood. 2008 112 : 100A.
161. Lee J. Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis. Ann Hematol. 2008 88 : 699 700.
162. Inoue Y, Suzuki T, Takimoto M, et al. Treatment with valproic acid for myelofibrosis with myeloid metaplasia. Ann Hematol. 2005 84 : 833 834.
163. Rambaldi A, Barbui T, Barosi G. From palliation to epigenetic therapy in myelofibrosis. Hematology Am Soc Hematol Educ Program. 2008 2008 : 83 91.
164. Plumb JA, Strathdee G, Sludden J, et al. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacyti-dine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000 60 : 6039 6044.
165. Reu FJ, Bae SI, Cherkassky L, et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol. 2006 24 : 3771 3779.
166. Reu FJ, Leaman DW, Maitra RR, et al. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res. 2006 66 : 2785 2793.
167. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia. 2008 22 : 23 30.
168. Aviram A, Witenberg B, Shaklai M, et al. Detection of methylated ABL1 promoter in philadelphia-negative myeloproliferative disorders. Blood Cells Mol Dis. 2003 30 : 100 106.
169. Ihalainen J, Juvonen E, Savolainen ER, et al. Calcitonin gene methylation in chronic myeloproliferative disorders. Leukemia. 1994 8 : 230 235.
170. Kumagai T, Tefferi A, Jones L, et al. Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia. Leuk Res. 2005 29 : 511 515.
171. Wang JC, Chen W, Nallusamy S, et al. Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Br J Haematol. 2002 116 : 582 586.
172. Oki Y, Jelinek J, Beran M, et al. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica. 2006 91 : 1147 1148.
173. Jones LC, Tefferi A, Idos GE, et al. RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia. Oncogene. 2004 23 : 7846 7853.
174. Hemavathy KC, Chang TH, Zhang H, et al. Reduced expression of TGF beta1RII in agnogenic myeloid metaplasia is not due to mutation or methylation. Leuk Res. 2006 30 : 47 53.
175. Li J, Bench AJ, Huntly BJ, et al. Mutation and methylation analysis of the transforming growth factor beta receptor II gene in polycythaemia vera. Br J Haematol. 2001 115 : 872 880.